With checkpoint inhibitors emerging as potential treatment approaches for advanced renal cell carcinoma, combining or sequencing them with vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors (TKIs) may reduce or delay disease progression, according to a recent review. Preliminary evidence suggests that VEGFR-TKIs can reverse immunosuppressive effects in the tumor microenvironment, potentially enhancing the effects of subsequent immunotherapy with checkpoint inhibitors. The authors discuss the potential role of first-line VEGFR-TKIs in priming the tumor microenvironment for immunotherapy.
Tannir N, Hammers H, Amin A. Impact of comorbidities on functional recovery from partial nephrectomy. [Published online ahead of print February 1, 2018]. Curr Med Res Opin. doi:10.1080/03007995.2018.1423960.
This Week's Must Reads
Must Reads in Renal Cell Carcinoma
First-line avelumab/axitinib for RCC benefits wide range of patients, Choueiri TK et al. GUCS 2019, Abstract 544.